

1 **TITLE:**

2 Isolation and Characterization of Human Adipocyte-derived Extracellular Vesicles Using
3 Filtration and Ultracentrifugation

4
5 **AUTHORS AND AFFILIATIONS:**

6 Naveed Akbar¹, Katherine E. Pinnick², Daan Paget¹, Robin P. Choudhury¹

7
8 ¹Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford,
9 Oxford, UK

10 ² Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

11
12 Corresponding Author

13 Naveed Akbar Naveed.Akbar@cardiov.ox.ac.uk

14
15 E-mail Addresses of Co-authors

16 Katherine Pinnick katherine.pinnick@ocdem.ox.ac.uk

17 Daan Paget daan.paget@lmh.ox.ac.uk

18 Robin P. Choudhury robin.choudhury@cardiov.ox.ac.uk

19
20 **KEYWORDS:**

21 Adipose, Exosomes, Microvesicles, Characterization, Signaling.

22
23 **SUMMARY:**

24 We describe the isolation of human adipocyte-derived extracellular vesicles (EVs) from gluteal
25 and abdominal adipose tissue using filtration and ultracentrifugation. We characterize the
26 isolated adipocyte-derived EVs by determining their size and concentration by Nanoparticle
27 Tracking Analysis and by western blotting for the presence of EV-protein tumor susceptibility
28 gene 101 (TSG101).

29
30 **ABSTRACT:**

31 Extracellular vesicles (EVs) are lipid enclosed envelopes that carry biologically active material
32 such as proteins, RNA, metabolites and lipids. EVs can modulate the cellular status of other cells
33 locally in tissue microenvironments or through liberation into peripheral blood. Adipocyte-
34 derived EVs are elevated in the peripheral blood and show alterations in their cargo (RNA and
35 protein) during metabolic disturbances including, obesity and diabetes. Adipocyte-derived EVs
36 can regulate the cellular status of neighboring vascular cells, such as endothelial cells and
37 adipose tissue resident macrophages to promote adipose tissue inflammation. Investigating
38 alterations in adipocyte-derived EVs in vivo is complex because EVs derived from peripheral
39 blood are highly heterogenous and contain EVs from other sources, namely platelets,
40 endothelial cells, erythrocytes and muscle. Therefore, the culture of human adipocytes provides
41 a model system for the study of adipocyte derived EVs. Here, we provide a detailed protocol for
42 the extraction of total small EVs from cell culture media of human gluteal and abdominal
43 adipocytes using filtration and ultracentrifugation. We further demonstrate the use of
44 Nanoparticle Tracking Analysis (NTA) for quantification of EV size and concentration and show

45 the presence of EV-protein tumor susceptibility gene 101 (TSG101) in the gluteal and abdominal
46 adipocyte derived-EVs. Isolated EVs from this protocol can be used for downstream analysis
47 including, transmission electron microscopy, proteomics, metabolomics, small RNA-sequencing,
48 microarray and utilized in functional in vitro/in vivo studies.

49

50 **INTRODUCTION:**

51 Extracellular vesicles (EVs) are lipid enclosed envelopes that carry biologically active material
52 such as proteins, microRNAs, metabolites and lipids. The term EVs denotes various
53 subpopulations, which include exosomes, microvesicles (microparticles/ectosomes) and
54 apoptotic bodies¹. EVs may serve as biomarkers because they are implicated in pathological
55 signaling and released into bio fluids including blood and urine. EVs can modulate the cellular
56 status of other cells locally in tissue microenvironments or through liberation into peripheral
57 blood². EVs bear features of their parent cell but differentiation of each sub population is
58 primarily based on EVs size and protein content such as EVs markers, including the presence of
59 tetraspanins (CD9, CD63 and CD81), tumor susceptibility gene 101 (TSG101) and ALG-2-
60 interacting protein X (ALIX). These protein markers are representative of the endosomal origin
61 (CD9, CD63 and CD81) for exosomes, which are generated inside multi-vesicular bodies or
62 represent proteins associated with budding or blebbing directly from the plasma membrane for
63 microvesicles. However, there is a significant overlap between these subpopulations and it is
64 difficult to distinguish individual sub-populations in complex bio fluids such as plasma, serum or
65 urine.

66

67 Metabolic disturbances, including obesity, insulin resistance, and perturbations in extracellular
68 glucose, oxygen and inflammation can alter the size and concentration of EVs and their cargo.
69 Adipocyte-derived EVs carry Perilipin A, adiponectin and show alterations in their protein and
70 RNA cargo during obesity and diabetes³⁻⁶. Adipocyte-derived EVs regulate the cellular status of
71 neighboring vascular endothelial cells⁷ and adipose tissue resident macrophages to promote
72 adipose tissue inflammation and insulin resistance⁸⁻¹¹. Investigating alterations in adipocyte-
73 derived EVs in vivo is complex because EV populations derived from complex biofluids such as
74 plasma, serum or urine contain EVs from multiple sources, such as platelets, endothelial cells,
75 erythrocytes and muscle, which are implicated in the pathogenesis of metabolic dysfunction
76 and disease.

77

78 The culture and in vitro differentiation of human preadipocytes, therefore, provides a model
79 system for the study of adipocyte derived EVs. Here, we provide a detailed protocol for the
80 extraction of total small EVs from cell culture media of human adipocytes using syringe
81 filtration and ultracentrifugation. Ultracentrifugation remains a popular method of isolation for
82 EVs because it is easily accessible and requires little prior specialist knowledge. However, other
83 methods such as precipitation, size exclusion chromatography and immunoaffinity capture
84 using tetraspanins enable EV isolation from a range of biofluids including plasma, serum, urine
85 and conditioned cell culture media. Each method, including the ultracentrifugation protocol
86 described here produce EV preparations of varying purity because the methods can co-isolate
87 soluble proteins and lipoproteins, which may mask as EVs. Combining this ultracentrifugation
88 protocol with other methods such as density centrifugation, size, exclusion chromatography

89 and immune-affinity capture dramatically increases the purity of isolated EVs. But similar to
90 ultracentrifugation, these other methods do not allow the capture of independent sub-
91 populations of EVs from complex samples such as blood, plasma and urine. Therefore, cultures
92 of selected cell populations remain one of the most robust methods for generating high yields
93 of cell specific EVs. Each EV method has a number of caveats and the choice of method can
94 impact the types of EVs isolated and their concentrations, which may bias downstream
95 mechanistic investigations into cellular and tissue signaling and determination of EV-cargo for
96 diagnostic studies; these methodological issues of EV isolation are discussed elsewhere and in
97 the limitation section below^{4,12}. Here, we describe the isolation of human adipocyte derived EVs
98 using filtration and ultracentrifugation. We further demonstrate the use of Nanoparticle
99 Tracking Analysis (NTA) for quantification of EV size and concentration and show the presence
100 of EV-protein tumor susceptibility gene 101 (TSG101) in our human adipocyte derived EVs.
101 Isolated EVs from this protocol can be used for downstream analysis, including transmission
102 electron microscopy, proteomics, metabolomics, small RNA-sequencing, microarray and utilized
103 in functional in vitro/in vivo studies.
104

105 **PROTOCOL:**

106

107 All methods were approved by the institutional ethics review board at the University of Oxford.

108 Adipose tissue was obtained by needle biopsy under local anesthetic from healthy volunteers.

109

110 **1. Preparation of cell culture medium and buffers**

111

112 1.1. Prepare a collagenase digestion buffer by dissolving collagenase H (1 mg/mL) in Hanks
113 Balanced Salt Solution (HBSS) (without calcium chloride and without magnesium chloride) and
114 sterile filter using a 0.2 µm pore syringe filter.

115

116 1.1.1. Prepare the collagenase digestion buffer no more than 10 minutes before use.

117

118 1.2. Prepare growth medium (GM) as follows: Dulbecco's Modified Eagle's Medium/Ham's
119 nutrient mixture F12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 100
120 units/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 0.5 ng/mL fibroblast
121 growth factor (FGF).

122

123 1.3. Prepare the basic differentiation medium (basic DM) as follows: DMEM/F12
124 supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, 17 µM
125 pantothenate, 100 nM human insulin, 10 nM triiodo-L-thyronine, 33 µM biotin, 10 µg/mL
126 transferrin and 1 µM dexamethasone.

127

128 1.4. Prepare complete differentiation medium (complete DM) by supplementing the basic
129 DM from step 1.3 with 0.25 mM 3-isobutyl-1-methylxanthine and 4 µM troglitazone.

130

131 1.5. Prepare 10 mM fatty acid stock solutions complexed to 10% essentially fatty acid free
132 bovine serum albumin (BSA) as follows.

133

134 1.5.1. Dissolve 16 g of BSA in 160 mL of DMEM/F12 medium and warm to 37 °C. In three
135 separate 50 mL conical tubes, weigh out 150 mg of sodium oleate, 139 mg of sodium palmitate
136 and 151 mg of sodium linoleate. Add 50 mL of the warmed BSA solution to each tube and mix
137 well by repeated vortexing.

138

139 1.5.2. Return the oleate and linoleate tubes to the 37 °C water bath for 15 minutes. Mix by
140 vortexing until completely dissolved.

141

142 1.5.3. For the palmitate solution place the tube in a 65 °C water bath for 2-3 minutes. Mix
143 vigorously by vortexing.

144

145 1.5.4. Repeat step 1.5.3. until fully dissolved – approximately 30 minutes.

146

147 NOTE: Some small particles may still be visible.

148

149 1.5.5. Sterile filter the fatty acid solutions using a 0.2 μm pore syringe filter.

150

151 1.5.6. Confirm the non-esterified fatty acids concentration of each stock solution using an
152 appropriate assay.

153

154 NOTE: Fatty acid stocks should be 10 mM (\pm 10%) to give a molar ratio of 6:1 between fatty acid
155 and BSA. If the concentration is outside this range the stock solution should be remade. Stock
156 solutions can be aliquoted and stored at -30 $^{\circ}\text{C}$.

157

158 **2. Digestion of human adipose tissue biopsies**

159

160 2.1. Slowly strain the contents of the biopsy syringe through a 200 μm sterile cell strainer
161 attached to a 50 mL conical tube so that the adipose tissue is collected in the strainer.

162

163 2.2. Transfer the strainer to a new 50 mL conical tube and wash the adipose tissue three
164 times with 10 mL of HBSS.

165

166 NOTE: It may be necessary to remove blood clots and fibrous tissue with surgical scissors or to
167 repeat the HBSS wash to remove excess red blood cells.

168

169 2.3. Weigh the washed tissue.

170

171 NOTE: We typically obtain 400-800 mg of tissue by needle biopsy.

172

173 2.4. Put the collagenase digestion buffer in a sterile 50 mL conical tube and add the washed
174 tissue. Surgical scissors can be used at this step to mince the tissue into equal sized pieces.

175

176 NOTE: Use 5 mL of buffer per 0.5 g tissue. For larger tissue, samples can be minced in a Petri
177 dish.

178

179 2.5. Place the tube into a 37 $^{\circ}\text{C}$ shaking water bath and incubate for 35 - 40 minutes.

180

181 NOTE: Following successful digestion the solution should appear milky. If small pieces of tissue
182 are still visible shake by hand for a further 10 - 20 s.

183

184 **3. Isolation of preadipocytes**

185

186 3.1. To pellet the preadipocyte fraction centrifuge at 1000 x *g* for 5 minutes.

187

188 3.2. Aspirate and discard the floating adipocyte layer and supernatant leaving approximately
189 1 mL of HBSS covering the cell pellet.

190

191 3.3. Resuspend the pellet in 5 mL of HBSS and pass the cell suspension through a 250 μm
192 pore size mesh followed by a 100 μm mesh to remove any undigested material. Collect the cell
193 suspension in a 15 mL conical tube.

194

195 3.4. Centrifuge at 1000 x *g* for 5 minutes.

196

197 NOTE: After this step, the preadipocyte fraction can be treated with a red blood cell lysis
198 solution if red blood cell contamination is an issue.

199

200 3.5. Aspirate and discard the supernatant.

201

202 3.6. Resuspend the cell pellet in 5 mL of GM (step 1.2) and seed into a 25 cm^2 adherent
203 tissue culture flask. Place the flask in a cell culture incubator (5% CO_2 , 37 $^\circ\text{C}$).

204

205 **4. Maintenance of preadipocyte cultures**

206

207 4.1. Replace the GM every 2 days while the cells are proliferating

208

209 NOTE: Cell proliferation rates may vary between donors.

210

211 4.1.1. When the cells reach approximately 80% confluence transfer them to a 75 cm^2 adherent
212 tissue culture flask. Remove the GM and wash the cells with phosphate buffered saline (PBS).

213

214 4.1.2. Discard the PBS and add 0.5 mL of highly purified cell dissociation enzymes to
215 disassociate the attached cells. Incubate at 37 $^\circ\text{C}$ for 5 minutes.

216

217 4.1.3. Tap the flask sharply to release the cells and add 5 mL of GM. Collect the cell suspension
218 in a 15 mL conical tube.

219

220 4.2. Centrifuge at 1000 x *g* for 5 minutes

221

222 4.3. Aspirate and discard the supernatant. Resuspend the cell pellet in 5 mL of GM and
223 transfer to a 75 cm^2 flask. Top up the GM to a final volume of 12 mL and replace the flask in the
224 cell culture incubator (5% CO_2 , 37 $^\circ\text{C}$).

225

226 NOTE: To maintain the cells continue to change the GM every 2-3 days. When the cells reach
227 80% confluence repeat steps 4.2-4.3 and divide the cells 1:3 into new 75 cm^2 flasks. This can be
228 repeated for several passages until sufficient number of cells have been generated for the
229 experimental set up. We would not recommend more than 10 passages as proliferation and
230 differentiation capacity of these preadipocytes declines.

231

232 **5. Seeding preadipocytes for adipogenic differentiation**

233

234 5.1. Count the cells using a hemocytometer and seed 200,000 cells into multiple wells of a 6
235 well plate in 2 mL of GM. Alternatively seed 3.5 million cells per T175 cm² flask in 22 mL of GM
236 media.

237
238 5.2. Allow the cells to proliferate for a further 2--4 days until they reach full confluence,
239 changing the GM on the second day of culture.

240
241 5.3. To begin adipogenic differentiation remove the GM and replace with complete DM for 4
242 days (2 mL of complete DM per well of a 6 well plate or 22 mL for a T175 cm² flask).

243
244 NOTE: Replace with fresh complete DM on day 2.

245
246 5.4. On day 4 remove the complete DM and replace with 2 mL basic DM supplemented with
247 22.5 µM oleate, 15 µM palmitate and 12.5 µM linoleate to give a total fatty acid concentration
248 of 50 µM per well of a 6 well plate or 22 mL for a T175 cm² flask. Replace with media every 2
249 days for a further 10 days.

250
251 NOTE: From day 7 onwards lipid droplets should be visible in the differentiating preadipocytes.

252
253 5.5. On culture day 14 collect the media from the cells for isolation of adipocyte-derived EVs

254 255 **6. Preparation of cell culture supernatant for extracellular vesicle isolation or storage** 256 **and future extracellular vesicle isolation**

257
258 6.1. Remove cell culture supernatants from each 6 well plate and combine. Add to a 15 mL
259 tube or remove all the cell culture supernatant from a T175 cm² flask and add to a 50 mL tube.

260
261 6.2. Centrifuge for 10 minutes at 4 °C at 1000 x g.

262
263 6.3. Decant supernatant into a new clean 15 mL or 50 mL tube by pouring, respectively.

264
265 6.4. Remove the barrel of a 10 mL syringe and attach 0.45 µm syringe filter.

266
267 6.5. Pour in the supernatant to the syringe reservoir and apply gentle pressure at the syringe
268 barrel opening with a thumb or palm until the cell culture supernatant freely passes through
269 the filter.

270
271 NOTE: The speed of this filtration step can vary depending on the type of syringe filter.

272
273 6.6. Collect the filtrate in a clean 50 mL tube.

274
275 NOTE: If required the conditioned filtered media can be stored at this point at -80 °C for several
276 weeks. When required defrost the cell culture supernatants at 4 °C and centrifuge for 10
277 minutes at 4 °C at 1000 x g. Decant supernatant into a clean tube by pouring before

278 continuing with the EV isolations.

279

280 6.7. Collect the filtrate in a clean 50 mL tube.

281

282 7. Isolation of extracellular vesicles

283

284 7.1. Label a 13 mL ultracentrifugation tube by drawing a circle at the bottom of the tube,
285 where the expected EV pellet will form and mark a line around the neck of the tube for
286 orientation in the ultracentrifugation tube rotor. Label the tube with a sample identifier.

287

288 7.2. Place tube in tube holder.

289

290 7.3. Attach a 16G needle to a 10 mL syringe, and remove the syringe barrel.

291

292 7.4. Remove the protective cover from needle and insert the needle into the neck of the
293 ultracentrifugation tube.

294

295 7.5. Pour cell culture supernatant directly into the syringe barrel to fill the
296 ultracentrifugation tube.

297

298 7.6. Top up the tube with PBS as necessary until full.

299

300 NOTE: Allow the tube to slightly overflow if necessary, ensuring there are no air spaces in the
301 ultracentrifugation tube and no air bubbles

302

303 7.7. Seal ultracentrifugation tube using a soldering iron, ensuring the tube is airtight by
304 squeezing the tube gently.

305

306 7.8. Place the ultracentrifugation tubes in the ultracentrifugation rotor, ensure the line
307 marked at the top of the tube and the circle drawn at the base of the tube are facing outwards,
308 where the EV pellet will form.

309

310 7.9. Ultracentrifuge for 2 hours at 120,000 x *g* at 4 °C.

311

312 7.10. Carefully remove the rotor from the ultracentrifuge.

313

314 7.11. Remove ultracentrifugation tubes from the rotor and place in the tube holder.

315

316 7.12. Attach a 16G needle to a 10 mL syringe.

317

318 7.13. Pierce the top of the ultracentrifugation tube and insert the needle 2 cm into the top of
319 the tube and aspirate the supernatant into the syringe.

320

321 7.14. Decant this EV-depleted supernatant into a 1.5 mL tube and freeze at – 80 °C.

- 322
- 323 7.15. Reinsert needle into the tube and carefully aspirate the remaining supernatant and
- 324 discard.
- 325
- 326 7.16. Cut the top of the tube with a pair of scissors.
- 327
- 328 7.17. Pour off the remaining supernatant in one quick action.
- 329
- 330 7.18. Allow the tube to hang upside down for 1 minute.
- 331
- 332 7.19. Pat dry any liquid that forms on the tube with paper towel.
- 333
- 334 7.20. Invert the tube and place in the tube holder.
- 335
- 336 7.21. Add 100 μ L of PBS to the tube.
- 337
- 338 7.22. Using the tip of a pipette gently dislodge the EV pellet at the base of the tube using a
- 339 circular motion in the area marked in step 7.1.
- 340
- 341 7.23. Vortex briefly (1-2 seconds), twice.
- 342
- 343 7.24. Label a new 13 mL ultracentrifugation tube by drawing a circle at the bottom of the
- 344 tube, where the expected EV pellet will form and mark a line around the neck of tube for
- 345 orientation in the ultracentrifugation tube rotor. Label tube with sample identifier.
- 346
- 347 7.25. Place tube in tube holder.
- 348
- 349 7.26. Add 12 mL PBS to a new ultracentrifugation tube using a clean syringe and needle.
- 350
- 351 7.27. Using a syringe and needle collect the 100 μ L EV sample and add to the tube. Carefully
- 352 mix the EVs and PBS and rinse the syringe and needle by gently collecting PBS and aspirating
- 353 into the tube.
- 354
- 355 NOTE: Avoid creating bubbles
- 356
- 357 7.28. Seal ultracentrifugation tube using a soldering iron, ensuring the tube is air tight by
- 358 squeezing the tube gently.
- 359
- 360 7.29. Place the ultracentrifugation tubes in the ultracentrifugation rotor, ensure the line
- 361 marked at the top of the tube and the circle drawn at the base of the tube are facing outwards.
- 362
- 363 7.30. Ultracentrifuge for 1 hour at 120,000 $\times g$ at 4 $^{\circ}$ C.
- 364
- 365 7.31. Carefully remove the rotor from the ultracentrifuge.

366

367 7.32. Attach a 16G needle to a 12 mL syringe.

368

369 7.33. Pierce the top of the ultracentrifugation tube and insert the needle 2 cm into the top of
370 the tube, aspirate the supernatant into the syringe and discard.

371

372 7.34. Cut the top of the tube with a pair of scissors.

373

374 7.35. Pour off the remaining supernatant in one quick action.

375

376 7.36. Allow the tube to hang upside down for 1 minute.

377

378 7.37. Pat dry any liquid that forms on the tube edge.

379

380 7.38. Place in the tube holder.

381

382 7.39. Add 100 μ L PBS to the tube.

383

384 7.40. Using the tip of a pipette gently dislodge the EV pellet at the base of the tube using a
385 circular motion in the area marked in step 7.24.

386

387 7.41. Vortex briefly (1 - 2 seconds), twice.

388

389 7.42. Pipette 100 μ L PBS/EV solution in to a clean 1.5 mL tube and keep on wet ice.

390

391 NOTE: EV are ready for downstream processing and may be frozen and stored at -80 $^{\circ}$ C.

392

393 8. Determination of EV size and concentration using Nanoparticle Tracking Analysis 394 (NTA)

395

396 8.1. Preparing the system

397

398 NOTE: A detailed method for the use of Nanoparticle Tracking Analysis (NTA) for determination
399 of EV size and concentration was reported by Mehdiani *et al.*¹³

400

401 8.1.1. Defrost samples and keep them at 4 $^{\circ}$ C.

402

403 8.1.2. Start the NTA software by clicking the software-icon.

404

405 8.1.3. The software will open in 'cell check' and prompt you to fill the flow cell with deionized
406 water. Fill a 10 mL syringe with deionized water and push into the machine, ensuring air
407 bubbles pass into the loading chamber.

408

409 8.1.4. Follow the on screen instructions to prepare the system through a quality check (QC).

410
411 8.1.5. The software will perform a cell check and give you a measure of 'cell quality'. This
412 should be very good to excellent.

413
414 8.1.6. Prepare the quality control consisting of a 100 nanometer polystyrene beads. Pipette 1
415 μL of the standard into 999 μL of deionized water (diluted stock). Subsequently, add 10 μL of
416 the diluted stock to 2.5 mL of deionized water (QC sample). Mix the solution by gently vortexing
417 for 2-3 seconds and by pipetting.

418
419 NOTE: Quality control samples should be prepared freshly every day but the initial diluted stock
420 sample is stable for 1 week at 4 °C.

421
422 8.1.7. Fill a 1 mL syringe with the 1 mL of the QC sample and remove all air bubbles from the
423 syringe.

424
425 8.1.8. Inject without introducing air bubbles into the NTA sample loading chamber by gently
426 tilting the tip of the syringe into the injection chamber, whilst simultaneously pushing the
427 plunger. Inject up to 950 μL of the QC sample into the chamber.

428 NOTE: Do not introduce air bubbles into the sample loading chamber.

429
430 8.1.9. The software will perform an auto alignment (focus the camera) and will check the
431 voltage for Z-potential readings – the voltage graph should be a smooth U-shaped curve.

432 NOTE: If the error message 'voltage too low error' the cell may be wet from cleaning or not
433 secure or there may be an air bubble.

434
435 8.1.10. Once the auto alignment/voltage check is complete, use the camera position drop down
436 to check all positions (0.1-0.9) for unusual marks – presence of these indicate the cell may need
437 flushing and/or cleaning.

438
439 8.1.11. Following QC the system will display 'ready for measurements'.

440
441 8.2. Determining EV size and concentration by Nanoparticle Tracking Analysis

442
443 NOTE: A detailed description for EV quantification using NTA is described elsewhere ¹³.

444
445 8.2.1. Prime the flow cell with PBS. Open the 'Pump/temp' tab and under 'pump' click 'run' for
446 pump 2 (PBS reservoir). This will run PBS through the cell for 1 minute then automatically stop.

447 NOTE: You may see particles in the chamber but these can be cleared by pushing 10 mL of PBS
448 through the loading port.

449
450 8.2.2. Fill a 10 mL syringe with PBS and load into the chamber with no air bubbles.

451
452 8.2.3. Create a protocol for the device to run that will measure multiple positions of the laser
453 and average the particles per frame.

454

455 8.2.4. Check the particle count is less than 5 (as close to 0 as possible) before proceeding –
456 flush with more PBS if necessary.

457

458 8.2.5. Prior to dilution, mix the EV sample by pipetting.

459

460 8.2.6. Dilute your sample 1:1000 in PBS and mix by pipetting. Fill a 1 mL syringe with your
461 sample and load into the chamber with no air bubbles.

462

463 8.2.7. Check that the particle count is within the acceptable range (the bar above your count
464 value should be in the green region, or close to it). If not, adjust your sample dilution
465 accordingly. In between samples and sample dilutions load 10 mL PBS into the front of the
466 machine to clear the chamber, then load 1 mL of your diluted sample.

467

468 NOTE: Each sample will independent dilution based on the concentration of the sample. The
469 particle count of the device should be between 50 - 200 particles per frame for accurate
470 measurements.

471

472 8.2.8. Go to the 'measurement' tab in the software.

473

474 8.2.9. Click the 'Run video acquisition' button.

475

476 8.2.10. Enter a sample name and select a destination folder to save the measurement.

477

478 8.3. Create an EV standard operating procedure (SOP)

479

480 8.3.1. Create, Save and Load an EV SOP – that will measure particle number and size at a
481 shutter speed of 100 and camera sensitivity of 80, 11 camera positions for 2 cycles – NOTE:
482 unless your sample has special requirements, there is no need to change these settingsSOP.

483

484 8.3.2. Enter the dilution of your sample and add any other notes you wish to add.

485

486 8.3.3. Click 'OK' and the software will automatically start recording.

487 NOTE: Do not touch the machine or nearby countertops during this time as vibrations will
488 influence the final readings.

489

490 8.3.4. Once finished, the software will automatically load a pop-up table showing average
491 particle counts and sizes for each camera position.

492

493 8.3.5. Camera positions with statistically unusual readings will automatically be excluded – if
494 you would like to manually exclude any camera positions (or re-include excluded ones for any
495 reason) click the check box to the left of the sample details.

496

497 8.3.6. Click 'continue' and the software will create and open a PDF of your sample and the size

498 **and concentration results.**

499

500 8.4. Statistical Analysis

501

502 8.4.1. NTA data was analyzed by one-way or two-way ANOVA with post-hoc Tukey correction.
503 Data are plotted as group means \pm standard deviation. A P value of <0.05 was considered
504 significant.

505

506 **REPRESENTATIVE RESULTS:**

507 We determined the quantity of EVs isolated from human gluteal adipocytes following the
508 described protocol. We calculated the size and concentration of adipocyte-derived EVs using
509 NTA (**Figure 1 A,B**). We utilized sham-media controls, which were equal volumes of media that
510 had not been in contact with cells, but cultured and subject to the isolation procedure
511 described above. We measured the adipocyte-derived EV concentration following the initial
512 isolation and after washing the isolated adipocyte EVs in PBS (**Figure 1 A,B**) and plotted the
513 group means \pm standard deviation (SD), which was analyzed by a two-way ANOVA with post-
514 hoc Tukey correction.

515

516 The concentration of adipocyte-derived EVs determined by NTA from the 1st isolation ranged
517 from 6.10×10^6 to 2.70×10^7 with a median of 2.60×10^7 EVs/mL (**Figure 1 A,B**). Following a PBS
518 wash there were significantly fewer adipocytes derived EVs per sample (**Figure 1 A,B**) ($P < 0.001$),
519 which ranged from 5.00×10^5 to 4.30×10^6 with a median of 2.70×10^6 EVs/mL. The sham-
520 media controls contained no EVs as determined by NTA (**Figure 1 A,B**). The modal size of EVs
521 from the first isolation was 125 nm and 105 nm following a PBS wash (**Figure 1 A,B**). The
522 described protocol was further applied to abdominal and gluteal derived-adipocytes from larger
523 T175 cm² flasks. These gluteal EV samples derived from T175 cm² flasks ranged in concentration
524 from 3.60×10^7 to 7.50×10^7 /mL with a median of 5.40×10^7 EVs/mL. Abdominal adipocyte
525 derived EVs from T175 cm² flasks ranged in concentration from 6.30×10^7 to 8.60×10^7 /mL with
526 a median of 7.60×10^7 EVs/mL (**Figure 1 C,D**). The modal size of EVs derived from the T175 cm²
527 flasks was 115 nm for gluteal EVs and 125 nm abdominal EVs. We confirmed the presence of
528 EV-protein in gluteal and abdominal derived EVs by immunoblotting for tumor susceptibility
529 gene 101 (TSG101) and found that abdominal and gluteal adipocyte cell pellets and abdominal
530 and gluteal adipocyte-derived EVs were positive for TSG101, whereas as sham-control media,
531 which had not been in contact with cell was negative (**Figure 1E**).

532

533 **FIGURE AND TABLE LEGENDS:**

534 **Figure 1: Size and distribution profile of adipocyte-derived EVs from cell culture media and**
535 **determination of EV-protein TSG101.** Total EV concentrations and size and concentration
536 distribution profiles as determined by Nanoparticle Tracking Analysis (NTA) from the 1st
537 isolation (N=5) and following washing with PBS (N=6). (C) Total concentrations and (D) size and
538 concentration distribution profiles determined by NTA for abdominal and gluteal derived EVs
539 from T175cm² flasks (N=4 per group). (E) Western blot of gluteal and abdominal derived EVs for
540 TSG101. Cell pellets and sham-media were used as positive and negative controls respectively.
541 Data are group means \pm standard deviation (SD). A one-way or two-way ANOVA with post-hoc

542 Tukey correction. *** P<0.001

543

544 **DISCUSSION:**

545 We demonstrate a protocol for the isolation of gluteal and abdominal adipocyte-derived EVs
546 from cell culture supernatants and determined their size and concentration by NTA^{7,14,15}. We
547 show that cultured human adipocytes produce and release EVs into the cell culture media,
548 which can be subsequently isolated using filtration and ultracentrifugation. We determined the
549 size and concentration profile of isolated adipocyte derived EVs and show that
550 ultracentrifugation likely co-isolated contaminants from the cell culture media and that washing
551 the isolated EV pellets in PBS significantly lowers their concentration in a second NTA
552 measurement. We further determined the purity of the isolated gluteal and abdominal derived
553 EVs by western blotting for TSG101 an EV-marker. Gluteal and abdominal derived EV
554 preparations were positive for TSG101 but importantly this was absent in control-media that
555 was not exposed to cells. The presented experiments used human adipocytes as the parent cell
556 generating EVs but the described method is suitable for other cell types including, endothelial
557 cells, vascular smooth muscle, skeletal muscle, immune cells and for the isolation of EVs from
558 patient platelet poor plasma or serum.

559

560 Adipocyte derived EVs are elevated in metabolic diseases and determining alterations in the
561 size and number of adipocyte EVs in vivo is complex because biological fluids such as blood
562 contain EVs from a number of cell sources that are also implicated in the pathogenesis of
563 metabolic disease, including EVs from endothelial cells, skeletal muscle, erythrocytes and
564 immune cells. The method described here allows determination of human adipocyte EVs, which
565 may provide a useful model for mechanistic studies investigating the factors that lead to EV
566 biogenesis in adipocytes, which is currently unknown. Importantly, determining adipocyte EV
567 biogenesis and how loading of particular RNAs, proteins and metabolites is orchestrated in
568 adipocyte EVs may reveal novel therapeutic opportunities to perturb pathogenic adipocyte EV
569 signaling in metabolic dysfunction. Detailed studies will provide a better understanding of how
570 EV size, number, biogenesis pathway and EV-cargo (RNA, proteins and metabolites) are altered
571 in response to disease or stimuli such as perturbations in oxygen, glucose, lipids and insulin.
572 Information on the role of environmental factors on adipocyte EV signaling in metabolic disease
573 and how adipocyte-derived EVs contribute towards adipose tissue inflammation may uncover
574 novel therapeutic targets in metabolic disease.

575

576 **Limitations**

577 **in vitro generation of adipocyte derived EVs**

578 The use of human preadipocytes in vitro provides a model system to study the release and
579 generation of adipocyte-derived EVs following in vitro adipocyte differentiation but there are a
580 number of limitations. In particular, in vitro derived adipocyte EVs are likely to differ from
581 adipose-derived EVs retrieved from bio fluids, such as plasma¹⁴ in their size, concentration, EV-
582 protein,-RNA, –metabolites and function. These EV differences could be influenced by other
583 non-adipocyte cells that are resident in adipose tissue in vivo, such as adipose tissue derived
584 stem cells, endothelial cells and macrophages, which are intimately linked to adipose tissue
585 physiology and have shown roles in adipose tissue pathology, including adipose tissue

586 inflammation.

587

588 It should be noted that the two week in vitro differentiation protocol described here may not
589 be sufficient to generate fully mature adipocytes equivalent to those seen in vivo; in vitro
590 differentiated adipocytes grown in a two-dimensional format display a different morphology to
591 in vivo cells and do not develop unilocular lipid droplets. Furthermore, the preadipocytes
592 described in this protocol are obtained from the adipose stromal-vascular fraction and we have
593 not assessed the contribution to EV pool from other cell types which were not completely
594 eliminated during the cell isolation.

595

596 The loss of important cell to cell interactions of adipocytes with other non-adipocytes in
597 adipose tissue may influence adipocyte EV generation, release, EV-protein and EV-RNA from
598 adipocytes and adipose tissue derived stem cells¹⁶. However, an assessment of how in vitro
599 derived adipocyte EVs differ from those produced in vivo has not been undertaken
600 exhaustively.

601

602 Primary tissue biopsies contain blood and therefore the derived cell cultures may contain
603 erythrocytes and erythrocyte derived EVs irrespective of the multiple washes and media
604 changes highlighted in our protocol. An additional red blood cell lysis step following isolation of
605 the stromal-vascular fraction may be necessary to eliminate the effects of erythrocytes on
606 adipocytes. This is important because erythrocyte derived EVs can impact the cellular function
607 of other cells¹⁷ and erythrocyte derived EVs are elevated in the presence of oxidative stress¹⁸
608 and in patients with metabolic syndrome^{19,20}. Therefore adipose tissue derived from metabolic
609 disease patients may contain elevated levels of erythrocyte derived EVs, which may influence
610 the in vitro phenotype of adipocytes.

611

612 Elimination of FBS

613 Our described protocol utilized FBS in the growth media during adipogenic differentiation but
614 subsequently the adipocytes were subject to multiple media changes before the final media
615 collection for the isolation of adipocyte derived EVs. Therefore, we assumed the overall risk for
616 contamination of FBS derived EVs in our EVs preparations to be low and subsequently
617 confirmed that residual EVs were not present in the cell culture media by western blotting for
618 TSG101. The isolation of cell cultured EVs from cell sources that require FBS must use EV-
619 depleted FBS or deplete bovine-EVs through ultra-centrifugation to prevent bovine-EVs
620 confounding adipocyte EV concentrations and analysis of adipocyte EV cargo. Depletion of
621 serum from adipocytes is known to alter their cellular responses²¹ and therefore investigation
622 must ensure that serum depletion or EV-depletion from serum renders their adipocyte cultures
623 truly representative of adipocyte biology.

624

625 Technical limitation of EV isolation using filtration and ultracentrifugation

626 We describe a method of ultracentrifugation with single use plastic tubes that require sealing
627 prior to ultracentrifugation for EV isolations. We acknowledge that these single use sealed
628 tubes may not be an economical option for many individuals and suggest exploration of similar
629 tubes, which do not require sealing and are reusable. However, investigators must ensure that

630 washing of reusable tubes is adequate and does not lead to progressive accumulation of
631 protein, lipid and RNA contaminants overtime, which may impact downstream investigations of
632 EV associated cargo or impact on cellular function studies.

633
634 The filtration and ultracentrifugation protocol described here has been used for numerous
635 years and multiple studies have highlighted the short fallings of this method, including the non-
636 specific isolations of contaminating cellular components such as cellular mitochondria, the
637 presence of nuclear fragments and constituents of the cell membrane. Furthermore, the
638 method described here will co-isolate lipoproteins produced by adipocytes or those present in
639 EV-depleted FBS. The method here may be further developed by the use of density
640 ultracentrifugation and size exclusion chromatography (SEC) to eliminate contaminating soluble
641 proteins and some lipoproteins. Coupled with PBS washing of the isolated EVs and SEC the co-
642 isolated contaminants can be limited but not completely eliminated. Therefore, users should
643 ensure the inclusion of appropriate controls, including a sham-media that has not been in
644 contact with cells to account for soluble proteins and lipoproteins in the culture media and an
645 EV-depleted supernatant control to demonstrate the successful isolation of EVs from
646 conditioned media that still contains soluble proteins and lipoproteins.

647
648 The isolation of EVs using filtration and ultracentrifugation relies on the operator ensuring
649 undue pressure is not applied to the cell culture supernatants whilst it is passed through the
650 bore of the filter or the bore of the needle/syringe. Application of undue force during this stage
651 of the described protocol may rupture EVs, influence the final EVs concentrations and generate
652 free RNA, proteins and metabolites, which were once encased in EVs. We have described a
653 method here, which doesn't require the syringe barrel and therefore the application of force to
654 the EVs in conditioned media as they pass through the filter or needle into their collection
655 reservoirs and ultracentrifugation tubes. Nonetheless, further care must be undertaken when
656 resuspending the EV pellet in PBS. Only a brief vortex must be used, as vigorous vortexing may
657 disrupt the EV membranes.

658
659 Following ultracentrifugation operators must be careful with the ultracentrifugation tubes as
660 not to disturb the EV pellet. This can be achieved by handling the tubes carefully and moving
661 them slowly between the ultracentrifugation rotor and the tube rack. Further care must be
662 taken when piercing a hole in the top of ultracentrifugation tube to aspirate the EV-depleted
663 supernatants. Inserting the needle into the top of the tube and aspirating the supernatants
664 quickly will create a vacuum in the syringe barrel, which can violently force the supernatant
665 back into the ultracentrifugation tube and disrupt the EV pellet. After cutting the
666 ultracentrifugation tube to pour off the remaining supernatant, care must be taken because the
667 EV pellet may become loose and pouring will discard the EV pellet. Alternatively, a syringe and
668 needle can be used to slowly remove the remaining supernatant without pouring or inverting
669 the tube.

670
671 Filtration and ultracentrifugation of supernatants for the isolation of EVs is a useful and
672 efficient method. But it is liable to the co-isolation of lipoproteins and soluble proteins. These
673 can be mitigated by washing the EVs with PBS (as described) but this will not eliminate all

674 contaminants. Soluble proteins can be eluted from the EV fraction by utilizing SEC), however
675 this method does not distinguish between lipoproteins and EVs. SEC-elutions that contains EVs
676 can be combined with ultracentrifugation to pellet EVs. Filtration and differential
677 ultracentrifugation is a preferred method of EV isolation over precipitation techniques, which
678 use polyethylene glycol because these precipitation methods co-isolate large quantities of
679 soluble proteins and lipoproteins in cell culture supernatants and other biological fluids.
680 Ultracentrifugation is likely to remain the most accessible form of EV isolation for many
681 because most laboratories are equipped with an ultracentrifuge, therefore mitigating initial
682 startup costs. But for many ultracentrifugation for EV isolation is hindered by the volume of
683 ultracentrifugation tubes and the starting volume of material. Several 100 mL's of culture
684 supernatants may be needed to produce sufficient EV quantity for downstream proteomics or
685 RNA-sequencing. However, it is likely that ultra-centrifugation techniques for EV isolation will
686 be accompanied by other techniques such as SEC and immuno-affinity capture using
687 tetraspanins CD9, CD63 and CD81 to improve the purity of isolated EVs. Other techniques such
688 as commercially available precipitation solutions and flow cytometry may be of some use in
689 specific investigations.

690

691 Purity of EV preparations

692 We confirmed the isolation of adipocyte derived EVs by western blotting for TSG101 but this
693 single western blot falls short of the guidelines published by the international society for
694 extracellular vesicles (ISEV). Further characterization of these adipocyte derived EVs would be
695 ideal using tetraspanins CD9, CD63 and CD81 to identify exosomes and markers of cellular
696 contamination such as histone H3, albumin and apolipoprotein A1.

697

698 The protocol presented here allows the isolation of EVs from cell culture supernatants from a
699 range of cell sources including adipocytes for determination of EV size, concentration, EV-
700 markers by western blot and utility in omics based technologies such as proteomics and RNA-
701 sequencing.

702

703 **ACKNOWLEDGMENTS:**

704 N.A. and R.C. acknowledge support by research grants from the British Heart Foundation the
705 Centre of Research Excellence, Oxford (N.A. and R.C.; RE/13/1/30181 and RE/18/3/34214),
706 British Heart Foundation Project Grant (N.A. and R.C.; PG/18/53/33895), the Tripartite
707 Immunometabolism Consortium, Novo Nordisk Foundation (NNF15CC0018486), the National
708 Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield
709 Benefaction for Medicine and the Wellcome Institutional Strategic Support Fund (ISSF). The
710 views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or
711 the Department of Health.

712

713 **DISCLOSURES:**

714 The authors have nothing to disclose

715

716 **REFERENCES:**

717 1 Théry, C. *et al.* Minimal information for studies of extracellular vesicles 2018

- 718 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and
719 update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*. **7** (1), 1535750, (2018).
- 720 2 Akbar, N. *et al.* Endothelium-derived extracellular vesicles promote splenic monocyte
721 mobilization in myocardial infarction. *JCI Insight*. **2** (17), (2017).
- 722 3 Xiao, Y. *et al.* Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis,
723 complications, and therapy. *Journal of Extracellular Vesicles* **8**, 1625677 (2019).
- 724 4 Akbar, N., Azzimato, V., Choudhury, R. P. & Aouadi, M. Extracellular vesicles in metabolic
725 disease. *Diabetologia*. **62** (12), 2179-2187, (2019).
- 726 5 Kobayashi, Y. *et al.* Circulating extracellular vesicles are associated with lipid and insulin
727 metabolism. *The American Journal of Physiology-Endocrinology and Metabolism*. **315** (4), E574-
728 E582, (2018).
- 729 6 Eguchi, A. *et al.* Circulating adipocyte-derived extracellular vesicles are novel markers of
730 metabolic stress. *Journal of Molecular Medicine (Berlin, Germany)*. **94** (11), 1241-1253, (2016).
- 731 7 Crewe, C. *et al.* An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by
732 Metabolic State. *Cell*. **175** (3), 695-708 e613, (2018).
- 733 8 Flaherty, S. E., 3rd *et al.* A lipase-independent pathway of lipid release and immune
734 modulation by adipocytes. *Science*. **363** (6430), 989-993, (2019).
- 735 9 Deng, Z. B. *et al.* Adipose tissue exosome-like vesicles mediate activation of
736 macrophage-induced insulin resistance. *Diabetes*. **58** (11), 2498-2505, (2009).
- 737 10 Kranendonk, M. E. *et al.* Human adipocyte extracellular vesicles in reciprocal signaling
738 between adipocytes and macrophages. *Obesity (Silver Spring)*. **22** (5), 1296-1308, (2014).
- 739 11 Song, M. *et al.* Adipocyte-Derived Exosomes Carrying Sonic Hedgehog Mediate M1
740 Macrophage Polarization-Induced Insulin Resistance via Ptch and PI3K Pathways. *Cellular*
741 *Physiology and Biochemistry*. **48** (4), 1416-1432, (2018).
- 742 12 Ramirez, M. I. *et al.* Technical challenges of working with extracellular vesicles.
743 *Nanoscale*. **10** (3), 881-906, (2018).
- 744 13 Mehdiyani, A. *et al.* An innovative method for exosome quantification and size
745 measurement. *Journal of Visual Experiments*. 10.3791/50974 (95), 50974, (2015).
- 746 14 Connolly, K. D. *et al.* Evidence for Adipocyte-Derived Extracellular Vesicles in the Human
747 Circulation. *Endocrinology*. **159** (9), 3259-3267, (2018).
- 748 15 Camino, T. *et al.* Vesicles Shed by Pathological Murine Adipocytes Spread Pathology:
749 Characterization and Functional Role of Insulin Resistant/Hypertrophied Adiposomes.
750 *International Journal of Molecular Sciences*. **21** (6), 2252, (2020).
- 751 16 Zhu, Y. *et al.* Extracellular vesicles derived from human adipose-derived stem cells
752 promote the exogenous angiogenesis of fat grafts via the let-7/AGO1/VEGF signalling pathway.
753 *Scientific Reports*. **10** (1), 5313, (2020).
- 754 17 Sadallah, S., Eken, C. & Schifferli, J. A. Erythrocyte-derived ectosomes have
755 immunosuppressive properties. *Journal of Leukocyte Biology*. **84** (5), 1316-1325, (2008).
- 756 18 Sudnitsyna, J. *et al.* Microvesicle Formation Induced by Oxidative Stress in Human
757 Erythrocytes. *Antioxidants (Basel)*. **9** (10), (2020).
- 758 19 Helal, O. *et al.* Increased levels of microparticles originating from endothelial cells,
759 platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative
760 stress. *Nutrition, Metabolism and Cardiovascular Diseases*. **21** (9), 665-671, (2011).
- 761 20 Agouni, A. *et al.* Endothelial dysfunction caused by circulating microparticles from

762 patients with metabolic syndrome. *The American Journal of Pathology*.**173** (4), 1210-1219,
763 (2008).
764 21 Park, J., Park, J., Nahm, S. S., Choi, I. & Kim, J. Identification of anti-adipogenic proteins
765 in adult bovine serum suppressing 3T3-L1 preadipocyte differentiation. *BMB Reports*. **46** (12),
766 582-587, (2013).
767

